

### DAFTAR PUSTAKA

1. Departemen Kesehatan Republik Indonesia. Pharmaceutical care untuk pasien penyakit arthritis rematik. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Ditjen Bina Kefarmasian dan Alat Kesehatan Departemen Kesehatan; 2006.
2. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset kesehatan dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2013.
3. Hansen KE, Elliott ME. Osteoarthritis, Pharmacotherapy: A Pathophysiologic Approach. 6th Edition. New York: McGraw-Hill; 2005.
4. Kinsella K, Taeuber. An aging world II, International population report. Washington DC: US. Bureau of the census; 1993.
5. Pramantara IDP, Setiati S. Buku Ajar Ilmu Penyakit Dalam Jilid III Ed.IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2007.
6. Pharmaceutical Care Network Europe Foundation. Classification for Drug Related Problems V6.02. Zuidlaren: Pharmaceutical Care Network Europe Foundation; 2010.
7. Cipolle RJ, Strand LM, Frakes MJ. Comorbidities and Drug Therapy Problems in Patients with Diabetes. Medication Management System, Inc; 2007.
8. Patrick M, Eichenberger, Markus L Lampert, Irene Vogel Kahmann, JW Foppe van Mil, Kurt E Hersberger. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Pharmacy World & Science, Volume 32, Issue 3; 2010.
9. Constantinides P. General Pathobiology. Chap 3. Appleton & Lange: Connecticut; 1994.
10. Siti, Maryam R. Mengenal Usia Lanjut dan Penangannya, Jakarta: Salemba Medica; 2008.
11. Thane P. The muddled history of retiring at 60 and 65. New Society; 1978
12. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on Health: Osteoarthritis. USA: Bethesda MD; 2002.
13. Priyanto. Farmakologi Dasar Untuk Mahasiswa Keperawatan dan Farmasi. Depok: Leskonsi; 2008.

14. American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise Prescription for Older Adults with Osteoarthritis Pain. Vol 49 Issue 6. America: Journal of the American Geriatrics Society; 2001.
15. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors. Boston: Annals of Internal Medicine; 2000.
16. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacopy, A Pathophysiological Approach, Sixth Edition. Appeton and Lange: Stamford; 2005.
17. Elin YS, Retnosari A, Joseph IS, I KA, A Adji PS, Kusnandar. ISO Farmakoterapi. Jakarta: PT. ISFI Penerbitan; 2008.
18. Abramson SB, Weissmann G. The Mechanism of Action of Nonsteroidal Anti-inflammatory Drugs, Arthritis Rheumatoid; 1989.
19. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Biol; 1997.
20. Breder CD, Dewitt D, Kraig RP. Characterization of Inducible cyclooxygenase in rat brain. J. Comp. Neurol; 1995.
21. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, Herschmann HR. In vivo glucocorticoids regulate COX-2 but not COX-1 in peritoneal macrophages. J. Pharmacol. Exp. Ther; 1994.
22. Goodman and Gilman. Dasar farmakologi terapi Vol. 1 Edisi 10. Jakarta: Penerbit Buku Kedokteran EGC; 2007.
23. Morrison BW, Daniels S, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific COX-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet, Gyneticol; 1999.
24. Malmstrom K, Daniels S, Rotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two COX-2 inhibitor in postoperative dental pain: a randomized, placebo and active comparator controlled trial. Clin ther; 1999.
25. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, et al. Preliminary study of safety and efficacy of SC 58.635, a novel cyclooxygenase 1 inhibitor: efficacy and safety in two placebo-controlled trials in Osteoarthritis and Rheumatoid Arthritis, and Studies of gastrointestinal and Platelet effects. Arthritis Rheum; 1998.

26. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized, controlled trial. *JAMA*; 1999.
27. Bensen WG, Fiechner JJ, Mc Millen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, et al. Treatment of Osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled-trial. *Mayo clin, proc*; 1999.
28. Madiyono Bambang, S Moeslichan MZ. *Dasar-dasar Metodologi Penelitian Klinis Edisi ke 4*. Jakarta: CV. Sagung Seto; 2011.
29. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebocontrolled trial. The rofecoxib osteoarthritis endoscopy multinational study group. *Arthritis rheum*; 2000.
30. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, et al. The safety profile, tolerability, and effective dose range of rofecoxib in treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. *Clint her*; 1999.
31. Ehrich EW, Schnitzer TJ, Mellwain H, Levy R, Wolfe F, Weisman M, Zeng Q, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee; a 6 week double-blind, placebo-controlled pilot study of rofecoxib. Rofecoxib osteoarthritis pilot study group. *J Rheumatol*; 1999.
32. Laine L, Halper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, et al. Randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastrointestinal mucosa of patients with osteoarthritis. Rofecoxib osteoarthritis endoscopy study group. *Gastroenterology*; 1999.
33. Kontinen YT, Kemppinen P, Segerberg M, Hukkanen M, Rees R, Santavirta S, Sorsa T, et al. Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain. *Arthritis rheum*; 1994.
34. Gebhart GF, McCornack KJ. *Neuronal plasticity. Implication for pain therapy*. Drugs; 1994.
35. Borda IT, Koff RS. *NSAIDs: A Profile of Adverse Effects*. Hanley and Belfus, Inc: Philadelphia, PA; 1992

36. Gabriel SE, Jaakimainen L, Bombardier C. Risk for serious gastrointestinal complication related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. *Ann Intern Med*; 1991.
37. Graham DY, White RH, Moreland LW et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. *Ann Intern Med*; 1993.
38. Kincaid-smith P. Effects of non-narcotic analgesic on the kidney. *Drugs*; 1986.
39. Sandler DP, Smith JC, Weinberg CR et al. Analgesic use and chronic renal disease. *N Engl J Med*; 1989.
40. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. *Kidney Int*; 1987.
41. Israel E, Fischer AR, Rosenberg MA. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. *Am Rev Respir Dis*; 1993.
42. Esteban NV, Loughlin T, Yergey AL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. *J Clin Endocrinol Metab*; 1991.
43. Lozada CJ. Medical Management of Osteoarthritis. *JCOMJ Clin. Outcomes Manage*; 2001.
44. Cipolle RJ, Morley PC, Strand LM. *Pharmaceutical Care Practice*. New York: McGraw-Hill McGraw Professions Division; 1998.
45. Starner CI, Gray SL, Guay DRP, Hajjar ER, Handle SM, Hanlon JT. Geriatric. In: Dippiro, J. T., Talbert, R L., Yee, G. C., Matzke, G. R., Wells, B. G. & Posey, L. M. (eds.) *Pharmacotherapy: A Pathophysiologic Approach*. Seventh ed. USA: The McGraw-Hill Companies, Inc; 2008.
46. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in Elderly Patients. *The American Journal of Geriatric Pharmacotherapy*; 2007.
47. Binu KM, Nimmy N John, Geo P Varghese. A Survey Of Drug Related Problems Identified By Community Pharmacy In South India. *India: International Journal Of Pharmaceutical, Chemical And Biological Sciences*; 2012.
48. Junior DPDL, Kheir N, Abriata JP, Rocha CED, Santos CBD, Pela IR. Impact of Pharmaceutical Care Intervention in the identification and resolution of

- drug-related problem and quality of life in a group of elderly outpatient in Ribeirao preto (SP). Brazil: Therapeutics and Clinical Risk Management; 2007.
49. Schmader KE, Hanlon JT, Pieper CF. Effects of Geriatric Evaluation and Management on Adverse Drug Reactions and Suboptimal Prescribing in the Frail Elderly. USA: Am J Med; 2004.
  50. Viktil KK, Blix HS, Moger TA, Reikvarn A. Polypharmacy as Commonly Defined is an Indicator of Limited Value in the Assessment of Drug-Related Problems. British Journal of Clinical Pharmacology; 2006.
  51. Madiyono Bambang, S Moeslichan MZ, Satroasmoro S, Budiman I, Purwanto SH. Dasar-dasar Metodologi Penelitian Klinis Edisi ke 4. Jakarta: CV. Sagung Seto; 2011.
  52. Arissa, MI. Pola Distribusi Kasus Osteoarthritis Di Rsu Dokter Soedarso Pontianak Periode 1 Januari 2008 - 31 Desember 2009. Pontianak: Jurnal Mahasiswa PSPD FK Universitas Tanjungpura; 2009.
  53. Sudoyo WA, Setiyohadi B, Alwi I, K Simadibrata M, Setiadi S. Buku Ajar Ilmu Penyakit Dalam Jilid III. Edisi V. Jakarta: Interna Publishing; 2009.
  54. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003;79:377–83.
  55. Isbagio H. Tiga Hal yang Paling Menonjol dari 100 Lebih Jenis Rematik edisi 16. Jakarta: Smart Living; 2009.
  56. Hartono F. Gambaran Pengukuran Algodisfungsi dengan Kuesioner Lequesne Pada Osteoarthritis Lutut [Skripsi]. Surabaya; 2011.
  57. Kusuma W, Angliadi E, Angliadi LS. Profil penderita osteoarthritis lutut dengan obesitas di instalasi rehabilitasi medik BLU RSUP Prof. DR. R. D Kandou manado. Manado. Jurnal e-Clinic (eCl). 2014 Maret. 2(1).
  58. Deu RP, Mogi ITh, Angliadi E. Gambaran kejadian nyeri lutut dengan kecurigaan osteoarthritis Lutut pada perawat di poliklinik rawat jalan BLU RSUP. Prof. DR. R. D. Kandou Manado. Jurnal e-Clinic (eCl). 2014 November. 2(3).
  59. Tamamoba K. Studi tentang Keteraturan Berobat Pasien Osteoarthritis Di Poliklinik Rematologi Rumah Sakit Umum (RSU) Prof. dr. R. D. Kandou Manado. Manado: Politeknik Kesehatan Kementerian Kesehatan RI; 2007.

60. Horikawa K, Kasai Y, Yamakawa T, Sudo A, Uchida A. Prevalence of osteoarthritis, osteoporotic vertebral fractures, and spondylolisthesis among the elderly in a Japanese village. *Journal of Orthopaedic Surgery*. 2006. 14(1).
61. Sunarti S, Ridwan M, Firdaus MM. *Komorbidity Pasien Geriatri Dengan Osteoarthritis Genu Di Rumah Sakit Dr. Saiful Anwar Malang*. Malang: Fakultas Kedokteran Universitas Brawijaya; 2011.
62. Pinzon R. *Komorbidity nyeri pada pasien lanjut usia*. Yogyakarta: CDK-226 42 (3); 2015.
63. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. *Ann Fam Med*. 2005;3:223-8.
64. Wolff JL, Starfi eld B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. *Arch Intern Med*. 2002;162; p. 2269-76.
65. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The slone survey. *JAMA*. 2002 Jan 16;287:337-44.
66. Binfar dan Alkes Departemen Kesehatan RI. *Pedoman Pelayanan Farmasi (Tata Laksana Terapi Obat) Untuk Pasien Geriatri*. Direktorat Jenderal Bina Kefarmasian Dan Alat Kesehatan Departemen Kesehatan RI: Jakarta; 2006.
67. Al Ghamdi AA. The co-morbidities and mortality rate among rheumatoid arthritis patients at the western region of Saudi Arabia. *JKAU Med Sci*. 2009;16(3):15-29.
68. Dominick KL, Dudley TK, Coffman CJ, Bosworth HB. Comparison of Three Comorbidity Measures For Predicting Health Service Use in Patients With Osteoarthritis. *American College of Rheumatology*: 53(5); October 2005.
69. Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: A case control study of general practice consultants in England and Wales. *Ann Rheum Dis*. 2004;63:408-14.
70. Chan KW, Ngai HY, Ip K, Lam KH, Lai WW. Co-morbidities of patients with knee osteoarthritis. *Hong Kong Med J*. 2009;15:168-72.
71. Vallano A, Malouf J, Payrulet P, Banos JE. Analgesic use and pain in the hospital settings. *Barcelona: Eur J Clin Pharmacol* 63:619–626; 2007.

72. Meilissa G. Pola Penggunaan Analgesik pada Pasien Closed dan Opened Fraktur yang Menjalani Bedah Ortopedi dan Rawat Inap di Rumah Sakit Pertamina Balikpapan Periode Januari 2006-Januari 2007. Surabaya: Kementerian Riset dan Teknologi Republik Indonesia; 2007.
73. Craen de, Anton JM. Analgesic efficacy and safety of paracetamol-codeine combinations. *British Medical Journal*; Aug 10, 1996; 313, 7053. August 1996.
74. Burke, A., Smyte E., Fitz Gerald G. A., Analgesic-antipyretic agents; pharmacotherapy of gaout. In: Brunton, L.L (eds). *Goodman and Gilman's The Pharmacological Basic of Therapeutics*. Ed. 11st. New York: McGraw-Hill. Ch. 26. 2006.
75. Schug, S.A. Combination Analgesia in 2005 – A Rational Approach: Focus on Parasetamol-Tramadol. *Clin Rheumatol* 25 Suppl 1:S16-21. 2006.
76. Ningsih. *Interaksi Obat Pada Pasien di Poliklinik Geriatri Perjan RS Dr. Cipto Mangunkusumo* [Skripsi]. Jakarta; 2004.
77. Restalita. *Evaluasi Interaksi Obat Pada Peresepan Pasien Lanjut Usia di Puskesmas Pancoran Mas Kota Depok* [Skripsi]. Depok; 2010.
78. Direktorat Bina Farmasi Komunitas dan Klinik. *Pedoman Pelayanan Farmasi (Tata Laksana Terapi Obat) Untuk Pasien Geriatri*. Jakarta: Departemen Kesehatan RI; 2004.
79. Gumi VC, Larasanty LPF, Udayani NNW. *Identifikasi Drug Related Problems Pada Penanganan Pasien Hipertensi di UPT Puskesmas Jembrana*. Denpasar: Jurusan Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam Universitas Udayana; 2012.
80. American Pharmacist Association. *Drug Information Handbook 22<sup>nd</sup> edition*. USA: Lexi-comp Inc: 2013.
81. Wells BG, Dipiro JT, Schwinghammer TL, Dipiro CV. *Phamacotherapy Handbook*. New York: The McGraw-Hill Companies; 2009.
82. John Hopkins Medicine. *Antibiotic Guideline 2014-2015*. United States: John Hopkins Medicine; 2015.